Depression in chronic heart failure: novel pathophysiological mechanisms and therapeutic approaches

Bibliography

• WELLS K, STEWART A, HAYS R et al: The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA (1998) 262:914–919.
   Google Scholar
• GOLDMAN LS, NIELSEN NH, CHAMPION HC: Awareness, diagnosis, and treatment of depression." Gen. Intern. Med. (1999) 14:569–580.
   PubMed Web of Science ®Google Scholar
• ARTINIAN NT, ARTINIAN CG, SAUNDERS MM: Identifying and treating depression in patients with heart failure. Cardiovasc. Nurs. (2004)19(6 Suppl.):547–556.
   Google Scholar
• HAVRANEK EP, WARE M, LOWES BD: Prevalence of depression in patients with congestive heart failure. Am. J. Cardiol (1999) 84:348–350.
   PubMed Web of Science ®Google Scholar
• KOENIG H: Depression in hospitalized older patients with congestive heart failure. Gen. Hosp. Psychiatry (1998) 20:29–43.
   PubMed Web of Science ®Google Scholar
• SKOTZKO C, KRICHTEN C, ZIETOWSKI G et al: Depression is common and precludes accurate assessment of functional status in elderly patients with congestive heart failure. J. Cardiac. Fail. (2000) 6:300–305.
   PubMed Web of Science ®Google Scholar
• JIANG W, ALEXANDER J, CHRISTOPHER E et al.: Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch. Intern. Med. (2001) 161:1849–1856.
   PubMed Web of Science ®Google Scholar
• ••Retrospective clinical trial demonstratinghigh rates of mortality and hospital readmission in HF patients with depressive symptoms.
   Google Scholar
• JOYNT KE, WHELLAN DJ, O'CONNOR CM: Why is depression bad for the failing heart? A review of the mechanistic relationship between depression and heart failure. J. Card Fail. (2004) 10(3):258–270.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB SS, KHATTA M, FRIEDMANN E et al: The influence of age, gender and race on the prevalence of depression in heart failure patients. J. Am. Coll. Cardiol (2004) 43(9):1542–1549.
   PubMed Web of Science ®Google Scholar
• FRIEDMANN MM, GRIFFIN JA: Relationship of physical symptoms and physical functioning to depression in patients with heart failure. Heart Lung (2001) 30:98–104.
   PubMed Web of Science ®Google Scholar
• HEVRAREK EP, SPERTUS JA, MASOUDI FA, JONES PG, RUMSFELD JS: Predictors of the onset of depressive symptoms in patients with heart failure. J. Am. Coll. Cardiol (2004) 44(12):2333–2338.
   PubMed Web of Science ®Google Scholar
• •A multi-centre prospective cohort study of outpatients with CHF showing that social factors and health status predict the development of depression in this patient population.
   Google Scholar
• ABRAMSON J, BERGER A, KRUMHOLZ HM, VACCARINO V: Depression and risk of heart failure among older persons with isolated systolic hypertension. Arch. Intern. Med. (2001) 161:1725–1730.
   PubMed Web of Science ®Google Scholar
• RUMSFELD JS, HAVRANEK EP, MASOUDI F et al.: Depressive symptoms are the strongest predictors of short-term declines in health status in patients with heart failure." Am. Coll. Cardiol (2003) 42:1811–1817.
   Google Scholar
• VACCARINO V, KASL S, ABRAMSON J, KRUMHOLZ HM: Depressive symptoms and risk of functional decline and death in patients with heart failure. I Am. Coll. Cardiol (2001) 38:199–205.
   PubMed Web of Science ®Google Scholar
• MURBERG TE, FURZE G: Depressive symptoms and mortality in patients with congestive heart failure: a six-year follow-up study. Med. Sci. Monk (2004) 10(12):CR643-CR648.
   Google Scholar
• SULLIVAN MD, LEVY WC, CRANE BA, RUSSO JE, SPERTUS JA: Usefulness of depression to predict time to combined end point of transplant or death for outpatients with advanced heart failure. Am. J. Cardiol (2004) 94:1577–1580.
   PubMed Web of Science ®Google Scholar
• MUSSELMAN DL, EVANS DL, NEMEROFF CB: The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch. Gen. Psychiatry (1998) 55:580–592.
   PubMed Web of Science ®Google Scholar
• DAVIDSON JR, MELTZER-BRODY SE: The under-recognition and under-treatment of depression: what is the breadth and depth of the problem?' Clin. Psychiatry (1999) 60\(Suppl. 7):4–9.
   Google Scholar
• JACOB S, SEBASTIAN JC, ABRAHAM G: Depression and congestive heart failure: are antidepressants underutilized? Eur. J. Heart Failure (2003) 5 (3):399–400.
   Google Scholar
• O'CONNOR CM, JOYNT KE: Depression: are we ignoring an important comorbidity in heart failure?' Am. Coll. Cardiol (2004) 43(9):1550–1552.
   PubMed Web of Science ®Google Scholar
• EVANGELISTA LS, BERG J, DRACUP K: Relationship between psychosocial variables and compliance in patients with heart failure. Heart Lung (2001) 30:294–301.
   PubMed Web of Science ®Google Scholar
• KRUMHOLZ HM, BUTLER J, MILLER J et al: Prognostic importance of emotional support for elderly patients hospitalized with heart failure. Circulation (1998) 97:958–964.
   PubMed Web of Science ®Google Scholar
• MURBURG TA, BRU E: Social relationships and mortality in patients with congestive heart failure. .1 Psychosom. Res. (2001) 51:521–527.
   PubMed Web of Science ®Google Scholar
• MANN DL: Mechanisms and models in heart failure: a combinatorial approach. Circulation (1999) 100:999–1008.
   PubMed Web of Science ®Google Scholar
• MANN DL, YOUNG JB: Basic mechanisms in congestive heat failure: recognizing the role of pro-inflammatory cytokines. Chest (1994) 105:897–904.
   PubMed Web of Science ®Google Scholar
• ANKER SD, VON HAEHLING S: Inflammatory mediators in chronic heart failure: an overview. Heart (2004) 90:464–470.
   PubMed Web of Science ®Google Scholar
• ADAMOPOULOS S, PARISSIS J, KREMASTINOS D: A glossary of circulating cytokines in chronic heart failure. Eur. J. Heart Fail. (2001) 3:517–526.
   PubMed Web of Science ®Google Scholar
• SETA Y, SHAN K, BOZKURT B, ORAL H, MANN DL: Basic mechanisms in heart failure: the cytokine hypothesis. J. Card. Fail. (1996) 2:243–249.
   PubMedGoogle Scholar
• VON HAEHLING S, JANKOWSKA EA, ANKER SD: Tumour necrosis factor-a and the failing heart: pathophysiology and therapeutic implications. Basic Res. Cardiol (2004) 99:18–28.
   PubMed Web of Science ®Google Scholar
• ADAMOPOULOS S, PARISSIS J, KREMASTINOS D: Endothelial dysfunction in chronic heart failure: clinical and therapeutic implications. Eur. J. Intern. Med. (2002) 13:233–239.
   PubMedGoogle Scholar
• MAES M: Major depression and activation of the inflammatory response system. Adv. Exp. Med. Biol. (1999) 461:25–46.
   PubMed Web of Science ®Google Scholar
• PASIC J, LEVY WC, SULLIVAN MD: Cytokines in depression and heart failure. Psychosom. Med. (2003) 65:181–193.
   PubMed Web of Science ®Google Scholar
• ••A review describing the implication ofcytokine activation in the pathogenesis of depression in CHE
   Google Scholar
• WATKINS LR, MAIER SF, GOEHLER LE: Cytokine-to-brain communication: a review and analysis of alternative mechanisms. Lai. Sci. (1995) 57:1011-1026.574Expert Op/n. Investig. Drugs (2005) 14(5)
   Google Scholar
• REICHENBERG A, YIRMIYA R, SCHOULD A et al: Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry (2001) 58:445–452.
   PubMed Web of Science ®Google Scholar
• PARISSIS J, ADAMOPOULOS S, RIGAS A et al: Comparison of circulating proinflammatory cytokines and soluble apoptosis mediators in patients with chronic heart failure with versus without symptoms of depression. Am. Cardiol. (2004) 94:1326–1328.
   PubMed Web of Science ®Google Scholar
• ••A clinical study describing elevated levelsof pro-inflammatory cytokines and soluble apoptosis inducers in patients with CHF and depression.
   Google Scholar
• DENOLLET J, CONRAADS VM, BRUTSAERT DL, DE CLERK LS, STEVENS WJ: Cytokines and immune activation in systolic heart failure: the role of type-D personality. Brant Behav. Immun. (2003) 17:304–309.
   PubMed Web of Science ®Google Scholar
• FLATHER MD, YUSUF S, KOBER L et al.: Long term ACE inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. Lancet (2000) 355:1575–1581.
   PubMed Web of Science ®Google Scholar
• EICHHORN EJ: Restoring function in failing hearts: the effects of 0-blockers. Am. J. Med. (1998) 104(2):163–169.
   PubMed Web of Science ®Google Scholar
• DIBBS Z, KURRELMEYER K, KALRA D et al: Cytokines in heart failure: pathogenetic mechanisms and potential treatment. Proc. Assoc. Am. Phys. (1999) 111(5):423–428.
   PubMedGoogle Scholar
• GULLESTAD L, AUKRUST P, UELAND T et al: Effect of high versus low dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J. Am. Coll Cardiol. (1999) 34:2061–2067.
   PubMed Web of Science ®Google Scholar
• OHTSUKA T, HAMADA M, HIASA G et al.: Effect of 0-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. I Am. Coll Cardiol. (2001) 37:412–417.
   PubMed Web of Science ®Google Scholar
• FRANCIS J, WEISS RM, FELDER RB: Central mineralocorticoid receptor blockade decreases plasma tumor necrosis factor in rats with congestive heart failure. Circulation (2001)104(Suppl. II) JI-I9 (Abstract).
   Google Scholar
• MOHLER ER, SORENSEN LC, GHALI JK et al.: Role of cytokines in the mechanism of action of amlodipine: the PRAISE heart failure trial. .j Am. Coll. Cardiol. (1997) 30:35–41.
   PubMed Web of Science ®Google Scholar
• ENDRES S, SINHA B, FULLE H: Amrinone suppresses the synthesis of tumor necrosis factor-a in human mononuclear cells. Shock (1994) 1:377–380.
   PubMed Web of Science ®Google Scholar
• DESWAL A, PETERSEN NJ, FELDMAN AM, WHITE BG, MANN DL: Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: a report from the vesnarinone trial. Chest (2001); 120:453–459.
   PubMed Web of Science ®Google Scholar
• DUBOST JJ, SOUBRIER M, RISTORI JM et al: An open study of the anti-TNF-a agent pentoxifylline in the treatment of rheumatoid arthritis. Rev Rheum. Engl. Ed. (1997) 64:789–793.
   PubMedGoogle Scholar
• SLIWA K, SKUDICKY D, CANDY G, WISENBAUGH T, SARELI P: Randomized trial of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet (1998) 351:1091–1093.
   PubMed Web of Science ®Google Scholar
• ANKER SD: Has the time arrived to use anticytokine therapy in chronic heart failure? Dial. Cardiovasc. Med. (2000) 5(3):162–170.
   Google Scholar
• MATSUMORI A, ONO K, NISHIO R, NOSE Y, SASAYAMA S: Amiodarone inhibits production of tumor necrosis factor-a by human mononuclear cells. A possible mechanism for its effect in heart failure. Circulation (1997) 96:1386–1389.
   Google Scholar
• MATSUMORI A, ONO K, NISHIO R et al.: Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain. Circulation (1997) 96:1501–1506.
   PubMed Web of Science ®Google Scholar
• SAMPAIO EP, SARNO EN, GALILLY R, COHN ZA, KAPLAN G: Thalidomide selectively inhibits tumor necrosis factor-a production by stimulated human monocytes. J. Exp. Med. (1991) 173:699–703.
   PubMed Web of Science ®Google Scholar
• KADOKAMI T, FRYE C, LEMSTER B et al.: Anti-tumor necrosis factor-a antibody limits heart failure in a transgenic model. Circulation (2001) 104:1094–1097.
   PubMed Web of Science ®Google Scholar
• SHERRY BA, GELIN J, FONG Y et a/.: Anticachectinitumor necrosis factor-a antibodies attenuate development of cachexia in tumor models. FASEB J. (1989) 3:1956–1962.
   Google Scholar
• CHUNG ES, PACKER M, LO KH, FASANMADE AA, WILLERSON JT: Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-a, in patients with moderate-to-severe heart failure: results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation (2003) 107:3133–3140.
   Google Scholar
• FEDORAK RN, GANG IA, ELSON CO et al: Recombinant human interleukin-10 in the treatment of patients with mild to moderately active Crohn's disease. The interleukin-10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 119:1781–1783.
   Google Scholar
• MADHUSUDAN S, FOSTER M, MUTHURAMALINGHAM SR et al: A Phase II study of etanercept (Enbrefrm), a tumor necrosis factor-a inhibitor in patients with metastatic breast cancer. Clin. Cancer Res. (2004) 10:6528–6534.
   PubMed Web of Science ®Google Scholar
• DESWAL A, BOZKURT B, SETA Y et al: Safety and efficacy of a soluble p75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation (1999) 99:3224–3226.
   PubMed Web of Science ®Google Scholar
• KLEIN B, BRAILLY H: Cytokine-binding proteins: stimulating antagonists. Immunol. Today (1995) 16:216–220.
   PubMedGoogle Scholar
• MANN DL, McMURRAY J, PACKER M et al.: Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 109:1594–1602.
   PubMed Web of Science ®Google Scholar
• SUFFREDINI AF, REDA D, BANKS SM, TROPEA M, AGOSTI JM, MILLER R: Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J. Immunol. (1995) 155:5038–5045.
   PubMed Web of Science ®Google Scholar
• MENON KV, STADHEIM L, KAMATH PS et al: A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am. J. Gastroenterol. (2004) 99:255–260.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, BAUMGERSTER SW SCHIFF MH et al: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl. I Med. (1997) 337:141–147.
   PubMed Web of Science ®Google Scholar
• ADAMOPOULOS S, PARISSIS J, GEORGIADES M et al: Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/ soluble Fas ligand in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy. Am. Heart J. (2002) 144:359–364.
   Google Scholar
• ADAMAPOULOS S, PARISSIS J, PARASKEVAIDIS I et al: Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy. Eur. Heart J. (2003) 24:2186–2196.
   PubMed Web of Science ®Google Scholar
• PARISSIS J, ADAMAPOULOS S, ANTIONIADES C et al: Effects of levosimendan on circulating proinflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am. Cardiol (2004) 93(10):1309–1312.
   PubMed Web of Science ®Google Scholar
• ADAMAPOULOS S, PARISSIS J, KARATZAS D et al: Physical training modulates proinflammatory cytokines and soluble Fas-soluble Fas Ligand system in patients with chronic heart failure. J. Am. Coll. Cardiol (2002) 39:653–663.
   PubMed Web of Science ®Google Scholar
• KOUKOUVOU G, KOUIDI E, IACOIVIDES A, KONSTANTINIDOU E, KAPRINSKIS G, DELIGGIANIS A: Quality of life, psychological and physiological changes following exercise training in patients with chronic heart failure. J. Rehabil Med. (2004) 36(1):36–41.
   PubMed Web of Science ®Google Scholar
• KOSTIS J, ROSEN R, COSGROVE N, SHINDLER D, WILSON A: Nonpharmacologic therapy improves functional and emotion status in congestive heart failure. Chest (1994) 106:996–1001.
   PubMed Web of Science ®Google Scholar
• ROOSE S, SPATZ E. Treating depression in patients with ischaemic heat disease: which agents are best to use and to avoid? Drug Sal: (1999) 20:459–465.
   Google Scholar
• GLASSMAN A, O'CONNOR R, CALIFF K et al: Sertraline treatment of major depression in patients with acute myocardial infarction or unstable angina. J. Am. Med. Assoc. (2002) 288:701–709.
   Web of Science ®Google Scholar
• ••Multi-centre, randomised, placebo-controlled trial demonstrating the clinical benefits and safety of sertraline treatment In post-MI patients.
   Google Scholar
• RASMUSSEN S, OVERO K, TANGHOJ P: Cardiac safety of citalopram: prospective trials and retrospective analyses. Clin. Psychopharmacol (1999) 19:407–415.
   PubMed Web of Science ®Google Scholar
• XIA Z, DE PIERRE JW, NASSBERGER L:Tricyclic antidepressants inhibit IL-6, IL-113 and TNF-a release in human blood monocytes and IL-2 and interferon-y in T cells. Immunopharmacology (1996) 34:27–37.
   PubMed Web of Science ®Google Scholar
• FLANIGAN M, ACCONE Q, LABURN H: Amitriptyline attenuates the febrile response to a pyrogen in rabbits. Basic Clin. Physiol Pharmacol (1992) 3:19–32.
   PubMedGoogle Scholar
• MAES M, SONG C, LI A et al.: Negativeimmunoregulatory effects of anti-depressants: inhibition of interferon-y and stimulation of interleukin-10 secretion. Neuropsychopharmacology (1999) 20:370–379.
   PubMed Web of Science ®Google Scholar
• SUZUKI E, SHINTANI F, KANBA S, ASAI M, NAKAKI T: Induction of interleukin-1 and interleukin-1 receptor antagonist mRNA by chronic treatment with various psychotropics in widespread area of rat brain. Neurosc. Lett. (1996) 215:201–204.
   PubMed Web of Science ®Google Scholar
• CAPURON L, GUMNICK J, MUSSELMAN D et al: Neurobehavioral effects of interferon-a in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology (2002) 26:643–652.
   PubMed Web of Science ®Google Scholar
• CASSIDY E, O'KEANE V: Depression andinterferon-a therapy. BE J. Psychiatry (2000) 176:494.
   PubMed Web of Science ®Google Scholar
• MOHR D, GOODKIN D, ISLAR J, HAUSER S, GENAIN C: Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis. Arch. Neurol (2001) 58:1081–1086.
   PubMed Web of Science ®Google Scholar
• MAES M, DELANGE J, RANJAN R et al: Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res. (1997) 66:1–11.
   PubMed Web of Science ®Google Scholar
• LANQUILLON S, KRIEG J, BENING-ABU-SHACH U, VEDDER H: Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology (2000) 22:370–379.
   PubMed Web of Science ®Google Scholar
• MIKOVA 0, YAKIMOVA R, BOSMANS E, KENIS G, MAES M: Increased serum tumor necrosis facto-alpha concentrations in major depression and multiple sclerosis. Eur. Neuropsychopharmacol (2001)11:203–208.
   PubMed Web of Science ®Google Scholar
• MAES M, VAN DER PLANKEN M, VAN GASTEL A et al. Blood coagulation and platelet aggegation in major depression. J. Affect. Disord. (1996) 40:35–40.
   Google Scholar
• HIDINA P, BAKISH D, CHUDZIK J, RAVINDRAN A, LAPIERRE Y: Serotonergic markers in platelets of patients with major depression: upregulation of 5-HT2 receptors. I Psychiatry Neurosci. (1995) 20:11–19.
   PubMed Web of Science ®Google Scholar
• VIKENES K, FARSTAD M, NORDREHAUG JE: Serotonin is associated with coronary artery disease and cardiac events. Circulation (1999) 100:483–489.
   PubMed Web of Science ®Google Scholar
• SHIMBO D, CHILD J, DAVIDSON K et al.: Exaggerated serotonin-mediated platelet reactivity as a possible link in depression and acute coronary syndromes. Am. J. Cardiol (2002) 89:331–333.
   PubMed Web of Science ®Google Scholar
• HELMESTE D, TANG S, REIST C et al:Serotonin uptake inhibitors modulate intracellular calcium mobilization in platelets. Eur. Pharmacol (1995) 288:373–377.
   PubMed Web of Science ®Google Scholar
• SHAPIRO P, LESPERANCE F, FRASURE-SMITH N et al: An open label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHATSertralineAnti-Depressant Heart Attack Trial. Am. Heart J. (1999) 137:1100–1106.
   PubMed Web of Science ®Google Scholar
• SEREBRUANY V, GLASSMAN A, MALININ A et al: Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sentraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation (2003) 108:939–944.
   PubMed Web of Science ®Google Scholar
• ••Multi-centre trial explaining the beneficialeffects of sertraline on the prognosis of post-MI patients through the drug-induced anti-platelet and endothelium-protective action.
   Google Scholar
• SHORES M, PASCULLY M, LEWIS N, FLATNESS D, VEITH R: Short-term sertraline treatment suppresses sympathetic nervous system activity in healthy human subjects. Psychoneuroendocrinology (2001) 26:433–439.
   PubMed Web of Science ®Google Scholar
• NAHSHONI E, AIZENBERG D, STASBERG B et al.: QT dispersion in the surface electrocardiogram in ederly patients with major depression. J. Affect. Disord. (2000) 60:197–200.
   PubMed Web of Science ®Google Scholar
• DUNBAR S, KIMBLE L, JENKONS L et al.: Association of mood disturbance and arrhythmia events in patients after cardioverter defibrillator implantation. Depress. Anxiety (1999) 9:163–168.
   PubMedGoogle Scholar
• McFARLANE A: Effect of sertraline on therecovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. Am. Heart J. (2001) 142:617–623.
   PubMed Web of Science ®Google Scholar
• CARNEY R, FREEDLAND K, STEIN P, SKALA J, HOFFMAN P, JAFFE A: Change in heart rate and heart rate variability during treatment for depression in patients with coronary heart disease. Psychosom. Med. (2000) 62:639–647.
   PubMed Web of Science ®Google Scholar
• •A clinical study showing the favourable effects of SSRIs on autonomic cardiac function in patients with coronary artery disease.
   Google Scholar